SCHEMBL8957112

SCHEMBL8957112

CCCCc1ncc(CC(NCc2ccccc2)C(=O)OCC)n1Cc1ccccc1Cl

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8957115 1.00 — —
SCHEMBL8957181 0.91 AGTR1 (0.56) —
SCHEMBL8957178 0.91 AGTR1 (0.56) —
SCHEMBL9204638 0.87 AGTR1 (0.52) —
SCHEMBL9204635 0.87 AGTR1 (0.52) —
SCHEMBL9209633 0.84 AGTR1 (0.56) —
SCHEMBL7432923 0.84 AGTR1 (0.60) —
SCHEMBL7432919 0.84 AGTR1 (0.60) —
SCHEMBL9209632 0.84 AGTR1 (0.56) —
SCHEMBL9214275 0.83 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5565480-A ANGIOTENSIN II RECEPTOR ANTAGONIST; USEFUL IN REGULATING HYPERTENSION, TREATMENT OF CONGESTIVE HEART FAILURE, RENAL FAILURE AND GLUCOMA SMITHKLINE BEECHAM CORPORATION (US) 1996-10-15 — — US disclosed
EP-0536262-A4 SUBSTITUTED HISTIDINES SMITHKLINE BEECHAM CORP (US) 1996-08-14 — — EP disclosed
US-5444081-A Treatment of hypertension, congestive heart failure, renal failure, glaucoma SMITHKLINE BEECHAM CORP (US) 1995-08-22 — — US disclosed
EP-0536262-A1 SUBSTITUTED HISTIDINES SMITHKLINE BEECHAM CORPORATION (US) 1993-04-14 — — EP disclosed
WO-1992000068-A1 SUBSTITUTED HISTIDINES SMITHKLINE BEECHAM CORPORATION (US) 1992-01-09 — — WO disclosed
Send feedback